Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) head-only MR-conditional approval for the Company’s Algovita SCS system.
Aziyo Biologics, Inc., a fully integrated regenerative medicine company, announced recently that it has received U.S. Food and Drug Administration (FDA) clearance of the CanGaroo Envelope device for use with implantable neurostimulator devices.
Medtronic plc (NYSE:MDT), a global leader in medical technology, and Nutrino Health Ltd., a leading provider of nutrition-related data services, analytics, and technologies, today announced the companies have entered into a definitive agreement under which Medtronic will acquire Nutrino.
Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals.
imec, Ghent University, and SEED Co., Ltd. have developed a contact lens with autonomous electronics, opening the door to unique applications such as lenses with sensors and/or drug-delivery systems for the treatment of eye disorders.
Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced it has entered into a definitive agreement to acquire DJO Global Inc. (“DJO”) from private equity funds managed by Blackstone for $3.15 billion in cash.
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, recently announced it has received CE Mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients.
Abbott (NYSE: ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe. People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation—a clinically proven, non-opioid treatment option for targeted chronic pain management.
Diabeloop announced today it has received the CE marking for the DBLG1™, its innovative technological solution to radically improve quality of life for T1D patients through better blood sugar management. This news represents an important step towards the commercial release of the product.
A new report from KPMG and RAPS sheds light on how prepared medical device companies are for the new European medical device regulation (MDR) as the 2020 compliance deadline approaches.
|
|
|
|
|
|
|
|
|